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ABSTRACT
Invasive malignant melanoma (MM) is an aggressive tumor with no curative 
therapy available in advanced stages. Nuclear corepressor (NCoR) is an essential 
regulator of gene transcription, and its function has been found deregulated in different 
types of cancer. In colorectal cancer cells, loss of nuclear NCoR is induced by Inhibitor 
of kappa B kinase (IKK) through the phosphorylation of specific serine residues. We 
here investigate whether NCoR function impacts in MM, which might have important 
diagnostic and prognostic significance. By IHC, we here determined the subcellular 
distribution of NCoR in a cohort of 63 primary invasive MM samples, and analyzed its 
possible correlation with specific clinical parameters. We therefore used a microarray-
based strategy to determine global gene expression differences in samples with similar 
tumor stage, which differ in the presence of cytoplasmic or nuclear NCoR. We found 
that loss of nuclear NCoR results in upregulation of a specific cancer-related genetic 
signature, and is significantly associated with MM progression. Inhibition of IKK activity 
in melanoma cells reverts NCoR nuclear distribution and specific NCoR-regulated 
gene transcription. Analysis of public database demonstrated that inactivating NCoR 
mutations are highly prevalent in MM, showing features of driver oncogene.
INTRODUCTION
Malignant melanoma (MM) is the most aggressive 
form of skin cancer accounting for most skin cancer 
deaths. Worldwide raising MM incidences have been 
recorded in the last decades, and currently about 48,000 
melanoma-related deaths occur every year. MM behavior 
mainly depends on the stage of disease but it varies from 
patient to patient, likely reflecting differences in the 
biological features of the tumor.
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Three main molecular pathways are found 
invariably deregulated in melanocytic tumors, including 
the RAS-RAF-MEK-ERK pathway (through mutation 
of BRAF, NRAS or KIT), the p16INK4A-CDK4-RB 
pathway (through mutation of INK4A or CDK4), and the 
ARF-p53 pathway (through mutation of ARF or TP53). 
Less frequently, other pathways such as the PI3K-AKT 
pathway (through mutation of NRAS, PTEN or PIK3CA) 
and the canonical Wnt signaling pathway (through 
mutation of CTNNB1 or APC genes) have been also 
associated with MM [1]. The RAS/RAF/MEK/ERK 
pathway is a crucial regulator of proliferation and cell 
survival in different physiologic and pathologic systems, 
and it is supposed to contribute to tumor progression in 
part through the activation of other downstream pathways 
such as NF-κB [2].
The NF-κB transcription factor is a homo- or hetero-
dimeric factor involving five different proteins (p50, p52, 
p65, c-Rel, and RelB), which plays an essential role in 
inflammation but also in the regulation of specific cellular 
functions such as apoptosis, proliferation, cell migration 
and metastasis. In the absence of external stimuli, NF-κB 
factors are mostly localized in the cytoplasm bound to 
the inhibitor of kappa B (IκB) proteins. Phosphorylation 
of IκB by the IκB kinase (IKK) complex leads to IκB 
ubiquitination and degradation, resulting in the release 
of NF-κB that then translocates to the nucleus to activate 
specific transcription. Thus, detection of nuclear NF-κB 
in both normal or neoplastic cells is indicative of NF-κB 
and IKK activation. Constitutive NF-κB/IKK activation 
has been previously found in different types of cancer 
including MM [3]. NF-κB plays an important role in 
preventing tumor cell apoptosis through the induction of 
anti-apoptotic genes such as the Inhibitors of Apoptosis 
(IAP) c-IAP1 and c-IAP2, or the melanoma inhibitor 
of apoptosis (ML-IAP) [4]. NF-κB also controls the 
expression of several chemokines, interleukin IL-1 and 
IL-6, the vascular endothelial growth factor (VEGF), as 
well as other factors that are known to impact in MM 
progression [4].
Besides their role in NF-κB activation, the IKK 
kinases regulate other substrates that are directly involved 
in the control of gene expression such as the silencing 
mediator of retinoic and thyroid hormone receptors 
(SMRT) and the nuclear receptor corepressor (NCoR). 
Both proteins are components of specific multi-protein 
complexes that contain histone deacetylases (HDACs) 
and act as critical regulators of gene repression. 
Alterations in the repressive function of HDAC and 
NCoR have been found associated to different types of 
cancer, although little is known on how their deregulation 
impacts in MM.
Because the IKK kinases promote the exportation 
of NCoR (cNCoR) and SMRT [5, 6] corepressors to 
cytoplasm in colorectal cancer (CRC) cells, we speculated 
that IKK activity might also affect NCoR distribution and 
specific gene transcription in MM, and tumor behavior. 
In this study, we have determined the subcellular 
distribution of NCoR, and the presence of nuclear p65-
NF-κB as a surrogate marker of IKK complex activation, 
in a set of human MM samples and melanocytic benign 
nevi. In addition, we have performed a large-scale gene 
expression analysis of MM samples with different levels 
of nuclear NCoR (nNCoR). Our results provide molecular 
information for the classification of MM subtypes, but 
also for prognostic and stratification of patients that could 
benefit for future personalized therapies.
RESULTS
NCoR shows a heterogeneous subcellular 
distribution in MM samples
By IHC, we found that NCoR protein exhibits a 
nuclear distribution in melanocytes of nevi samples. 
However, malignant melanocytes in MM samples 
showed a variable distribution, which in some cases 
resulted in the loss of nNCoR, occasionally associated 
with its cytoplasmic accumulation. More specifically, we 
observed that all in situ MM samples contained nNCoR 
similar to benign nevi. In contrast, the number of cells 
that lost nNCoR at the time of diagnosis correlated with 
increased tumor staging (Figure 1A and 1B), whereas the 
vast majority of metastatic samples disclosed an absent 
or minimal number of melanocytic cells with nNCoR. To 
determine the predictive value of loss of nNCoR in the 
primary tumors, we analyzed NCoR distribution in 63 
primary tumor samples from MM patients with different 
Breslow index using the non-parametric Spearman 
test. We found an inverse correlation (–0.628) between 
the percentages of nNCoR and the Breslow index (p < 
0.001), with samples showing lower percentage of nNCoR 
positive cells corresponding to the greater Breslow index 
(Figure 1B, Table 1). Next, we analyzed the possible 
relationship between loss of nNCoR and other prognostic 
indicators of MM. The analysis demonstrated a significant 
association between loss of nNCoR localization and 
higher mitotic index (p < 0.01) and a statistical trend 
with ulceration (p = 0.051) (see Table 1). However, no 
differences in other histopathological features (regression 
or prevalence of inflammatory component), age and 
gender were recorded between MM with nNCoR or 
cNCoR. Moreover, we did not detect any significant 
association between BRAF mutational status and NCoR 
distribution in 18 samples analyzed (all samples with 
available material).
Accumulation of cNCoR showed a correlation of 
0.551 with p65 nuclear distribution (indicative of IKK 
activation) (Figure 1C and 1D), which associated with 
MM progression. To further validate the relevance of 
NCoR localization as a predictive biomarker, patients were 
followed for a median of 59.4 months and analyzed based 
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on the presence of nNCoR. Mortality rate from all causes 
was significantly higher in those cases with less than 
70% of cells containing nNCoR (from now on cNCoR) 
compared with tumors maintaining nNCoR in more than 
70% of cells (from now on nNCoR), with overall survival 
(OS) at 5 years of 60.8% and 96% respectively. The OS 
curves of each group, considering a cut-off above and 
below 70% of cells carrying nNCoR, were significantly 
different between both groups with a log rank of 14.626 
and p < 0.001 (not depicted). Most importantly, the MM 
specific mortality (DSS) at 5 years was 29% in the cNCoR 
group compared to 0% in the nNCoR group (log rank 
11.568, p = 0.001) (Figure 2A). Considering those patients 
with skin limited disease at diagnosis (n = 49) significant 
differences in DSS were maintained (p = 0.010) between 
nNCoR and cNCoR (Figure 2B). Disease free survival 
(DFS) in the cNCoR group was of 67.1% at 3 years and 
58% at 5 years while no events were recorded in the 
nNCoR group (not depicted).
MM show different gene expression profiles 
depending on NCoR localization
To study the molecular bases that support the different 
behavior of patients carrying cNCoR and nNCoR tumors, 
we performed microarray expression analysis of invasive 
MM tumors with similar clinicopathologic characteristics 
and comparable mutational status for BRAF, NRAS and 
KIT (Table 2), which differ in the presence of cytoplasmic 
(n = 3) or nuclear (n = 4) NCoR. We included in the analysis 
3 benign nevi cases in which NCoR was exclusively located 
in the nucleus. To identify transcripts significantly altered 
in tumors with nNCoR or cNCoR we fixed a minimum 
arbitrary fold change of 1.2 and a p-value ≤ 0.05 as the 
threshold cut-off (submitted to GEO: GSE56494).
An initial analysis of global expression profiles 
demonstrate that whereas nevi samples clustered together 
in the Principal Component Analysis space, MM samples 
segregate randomly, and do not properly differentiate 
Figure 1: Loss of nuclear NCoR is associated with MM progression. (A) IHC analysis of NCoR distribution in MM samples 
at different stages of tumor progression. (B) Quantification of the percent of cells containing detectable nuclear NCoR in tumors with 
different Breslow Index. (C) Histoscore index showing the proportion of cells carrying nuclear (active) p65-NF-κB and nuclear NCoR in 
the indicated MM groups. (D) IHC analysis of p65-NF-κB distribution in nevi and MM samples at different stages of tumor progression. 
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between nNCoR and cNCoR tumors (not depicted). 
However, supervised analysis of the data identified a 185-
gene signature that clearly segregated cNCoR from nNCoR 
in our cohort of MM samples. Interestingly, nNCoR MM 
samples showed gene expression profiles comparable 
to the benign melanocytic nevi controls (Figure 3A). 
To identify putative targets of NCoR repression that are 
upregulated during MM progression, we focused on those 
transcripts that were significantly over-represented in the 
cNCoR group compared to the other groups. A total of 
73 genes were significantly upregulated in these samples 
including a subset of known cancer-related genes such as 
IL8 [7], the heat shock proteins HSPA1A/HSPA1B* and 
HSPA6 [8], the tumor suppressor TFPI2, SEMA3E that is 
involved in tissue development and cell adhesion [9], the 
cell cycle regulator MAGEC2/MAGEC3 [10], EYA4 which 
expression is altered in hepatocellular cacinoma, the protease 
inhibitor and tumor promoter Serpine 1 [11, 12], the matrix 
metaloprotease inhibitor TIMP3 [13], and the melanoma cell 
adhesion molecule MCAM [14] (Supplementary Table S1).
Table 1: Correlation between loss of nuclear NCoR and the different prognostic clinicopathological 
variables. Disease stage indicates the maximum stage reached at the end of the study.
Variable (n) nuclear NCoR % cells median [P25-P75] p-value
Stage
I–II (42) 70 [56–85]
0.001
III–IV (21) 45 [42–53]
Breslow index ρ = −0.628* <0.001
Mitotic index ρ = −0.546* <0.001
Nuclear p65 detection
Moderate/Intense ρ = −0.551* 0.027
Ulceration
Yes (14) 45 [42–69]
0.051
No (49) 70 [51–82]
Clark level
I–III (49) 70 [58–85]
<0.001
IV–V (14) 45 [39–52]
Regression features
No (40) 70 [45–85]
<50% (12) 60 [45–69] 0.675
> = 50% (11) 62 [50–78]
Tumor infiltrating lymphocytes**
TILs not identified/
Non Brisk (36) 70 [46–83]
0.256
TILs Brisk (27) 56 [44–80]
* Relationship assessed with Spearman’s Rho correlation coefficient
** TILs Not Identified: No lymphocytes present, or lymphocytes present but do not infiltrate tumor at all. TILs Non Brisk: 
Lymphocytes infiltrate melanoma only focally or not along the entire base of the vertical growth phase. TILs Brisk: 
Lymphocytes diffusely infiltrate the entire base of the vertical growth phase or the entire invasive component of the 
melanoma
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Functional analysis of an extended list of 654 genes 
(p < 0.05) performed in Ingenuity Pathway Analysis (IPA) 
and DAVID revealed that differentially expressed genes 
in nNCoR and cNCoR clustered into specific functional 
categories such as Toll-like signaling pathway, Cell Adhesion 
Molecules or negative regulation of apoptosis (Figure 3B), 
among others. Moreover, IPA identified NF-κB as the best 
candidate complex to connect all the observed changes in 
gene expression between nNCoR and cNCoR (Figure 3C).
IKK activity regulates NCoR distribution and 
gene expression in MM cells
Because we here identify NF-κB pathway as the 
node connecting the transcriptional program altered in 
cNCoR, and we previously associated the loss of nNCoR 
in colorectal cancer with increased activity of the NF-
κB kinases, IKK, we aimed to investigate whether IKK 
regulates NCoR distribution in MM cells.
By immunofluorescence, and using the cell lines 
SKMEL-37 as experimental model, we found that melanoma 
cells contain variable levels of nNCoR (5.56 ± 2.40%) when 
grown under standard conditions. Incubation with the IKK 
inhibitor BAY-11-7082 for 60 minutes resulted in a partial 
redistribution of cNCoR into the nuclear compartment, up to 
59.08 ± 12.19% (Figure 4A). By western blot and IF using 
a specific antibody detecting active phosphorylated IKK 
(at serines 180 or 181 for IKKα and IKKβ, respectively), 
we confirmed that BAY11-7082 effectively blocked IKK 
activation in these cells (Figure 4B and 4C). Next, we 
Figure 2: NCoR distribution predicts MM patient survival. Kaplan Meier analysis of the accumulated mortality by melanoma in 
the whole group of study (A) or in the subset of patients from stage I and II of the disease (B). The green line represent patients with tumors 
containing more than 70% of cells with nuclear NCoR, whereas the blue line represent tumors with less than 70% of cells with nuclear NCoR.
Table 2: Clinicopathologic characteristics and mutational status of the samples included in the 
expression microarray analysis (NM, nodular melanoma; SSM, superficial spreading melanoma; 
WT, wild type).
SAMPLE BRAF NRAS KIT MM subtype Location Breslow (mm)
cNCoR WT Q61L WT NM Arm 9.0
cNCoR V600R WT WT SSM Arm 5.3
cNCoR WT Q61R WT SSM Trunk 4.1
nNCoR V600E WT WT SSM Leg 4.4
nNCoR V600E WT WT NM Trunk 8.0
nNCoR WT Q61L WT NM Trunk 5.1
nNCoR V600R WT WT SSM Trunk 4.7
Nevus V600E WT WT
Nevus V600E WT WT
Nevus V600E WT WT
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investigated whether nNCoR redistribution, which was 
achieved after IKK inhibition, was sufficient to revert the 
basal levels of selected NCoR target genes identified in the 
microarray screening. By qRT-PCR we found that treatment 
of SKMEL-37 cells with BAY11-7082 for 60 minutes was 
sufficient to consistently repress IL8 expression but also 
other NCoR-regulated genes such as GAGE12J, HSPA6 and 
SEMA3A (Figure 4D), that are not direct targets of NF-κB.
NCoR is a putative driver of melanomagenesis
NCoR mutations have previously been found in 
different malignant disorders [15]. Thus, we investigated the 
possibility that mutations of the NCoR gene also contribute 
to tumorigenesis in MM. To that effect, we analyzed the 
existence of NCoR mutations in 369 MM samples from 
two public studies (see methods for details) and found 
23 missense, 4 synonymous and 1 truncating (stop-gain) 
mutations. Using the IntOGen-mutations platform that 
distinguishes cancer driver genes from passenger mutations 
[16], we tested whether NCoR exhibits any signal of 
positive selection typical of driver genes across the cohorts 
of MM tumors studied. We found that the mutations present 
in the Cancer Genome Atlas MM dataset samples as a 
group were significantly biased towards high functional 
impact (p = 0.002) with respect to background mutations 
in the same MM samples. Specific driver characteristics 
of NCoR mutations include the homogeneous distribution 
along the primary structure of the protein (Figure 5), and 
a high prevalence of missense and truncating (stop-gain) 
mutations [17] (Supplementary Table S2).
DISCUSSION
Malignant melanoma is an aggressive tumor without 
curative treatment in advance stages. Genetic alterations 
that activate the MAPK pathway such as mutation on 
BRAF, N-RAS, and c-Kit, as well as alteration in the p16-
CDK4-Rb-ARF-p53 and PTEN-PI3K function are found 
to promote tumor development through their interaction 
with other gene regulatory pathways such as NF-κB, and 
most of this information is currently used for therapy. 
However, and despite a significant knowledge that has 
been recently obtained on the molecular alterations leading 
to MM, the clinical outcome of MM is very variable 
among patients, and there are no reliable biomarkers 
Figure 3: Gene expression analysis of the two MM groups and non-malignant nevi. (A) Heatmap showing the results of the 
supervised analysis from genes differentially expressed between nNCoR and cNCoR cases. The list of genes appearing in the heatmap 
is detailed in Supplementary Table S1. (B) Selected Gene Ontology (Biological Processes) terms, KEGG (Kyoto Encyclopedia of Genes 
and Genomes) and Biocarta Pathways (http://www.biocarta.com/) obtained after a functional analysis in DAVID (http://david.abcc.ncifcrf.
gov/summary.jsp). (C) Top network as shown by Ingenuity Pathway Analysis (http://www.ingenuity.com/). Genes in green represent those 
overexpressed in nNCoR and in red overexpressed in cNCoR group.
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Figure 4: IKK activity regulates NCoR subcellular distribution and function in melanoma cells. (A) Immunohistochemistry 
of NCoR in SKMEL-37 melanoma cells untreated or treated for 60 minutes with the IKK inhibitor BAY11-7082. (B) Western blot analysis 
of cytoplasmic, nuclear and chromatin fractions of SKMEL-37 cells, treated with two different concentration of BAY11-7082 (Calbiochem) 
for 60 minutes. (C) qRT-PCR to determine the effect of IKK inhibition by BAY11-7082 (16 hours of treatment) in the levels of various 
NCoR target genes.
Figure 5: Distribution of somatic mutations along the sequence of the NCoR protein. Somatic mutations affecting NCoR 
across the 7000 samples of the dataset analyzed are color coded according to the tumor type.
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(beyond the Breslow index and the staging) that can 
predict MM behavior and whether particular individuals 
will benefit from the available treatments. In this context, 
there is a need of additional molecular clues that allow 
patient stratification and facilitates future personalized 
target treatments for MM.
Previous studies from our group identified 
SMRT and NCoR proteins as key regulators of specific 
developmental-related genes (such as Hes1 and Herp2) 
in the intestinal epithelium. Transcriptional control of 
Hes1 and Herp2 was totally lost in tumors carrying active 
IKK/NF-κB. We now found that loss of NCoR-mediated 
gene repression is not restricted tot colorectal cancer 
but is also found in MM. Most importantly, whereas in 
colorectal cancer sample alterations of NCoR distribution 
affected 100% of the studied samples [6], the cytoplasmic 
accumulation of NCoR in MM correlated with tumor 
progression, and it is linked with worse clinical outcome. 
Thus, evaluation of NCoR distribution in melanoma might 
provide of additional information about prognosis, which 
is not applicable to colorectal cancer. The differences 
in nuclear NCoR maintenance or loss between different 
tumor types might reflect differences in the mechanisms 
driving tumor transformation, differences in tumor stage 
at the time of diagnosis, or differential usage of particular 
signaling pathways (i.e. the NF-κB/IKK pathway).
Since there were no indications about the biologic 
significance of nNCoR loss in primary MM, we have 
here performed a high throughput transcriptome analysis 
of 4 MM samples with nNCoR and 3 MM samples 
that had lost nNCoR, but they all shared comparable 
histopathologic characteristics including the tumor 
stage (all stage II), the anatomic localization, and the 
distribution of BRAF, NRAS and Kit mutations (see 
Table 2). Our results led to the identification of a subset of 
genes that are significantly upregulated in the MM group 
without nNCoR (group 1), and some of them had been 
previously associated with cancer progression in other 
systems. We propose that this here-identified genetic 
signature could be refined and used as a predictive tool 
for MM. Not only this, but most of the identified genes 
participate of pathways or exert specific functions that are 
targetable, thus we propose that our information should be 
used to develop and test novel potential therapeutic agents 
for MM treatment.
On the other hand, it has been previously shown that 
the NF-κB pathway is active in different MM subtypes. 
NF-κB is a family of transcription factors that is composed 
of five different subunit that associate to form homo- and 
hetero-dimers. The p65/p50 dimer is the most commonly 
involved in NF-κB signaling, and for this reason detecting 
nuclear p65-NF-κB is a reasonable approximation of the 
activation status of the NF-κB pathway. In our MM series, 
we found that the presence of nuclear p65-NF-κB in MM 
cells was associated with advanced disease, although the 
correlation between nuclear p65-NF-κB and cytoplasmic 
accumulation of NCoR did not reach statistical 
significance in these tumors. However, since different 
NF-κB dimers are induced by IKK in a context dependent 
fashion and because NF-κB regulation is very complex, 
we directly tested the possibility that NCoR cytoplasmic 
export in MM was downstream of IKK. With this purpose, 
we used melanoma cells that showed variable levels of 
nNCoR. We found that these cells contain active IKK, and 
that inhibition of IKK by BAY11-7082 reverted nNCoR 
distribution leading to the transcriptional repression of 
specific NCoR target genes, which could have clinical or 
therapeutic implications. Interestingly, it was previously 
found that nNCoR loss in neuroblastoma is due to a non-
canonical activation of the NF-κB pathway by PEDF [18] 
that could also be explored in MM.
In conclusion, or results indicate that determination 
of NCoR distribution in MM can be used as a predictive 
factor, but most importantly as a criterion for patient 
stratification and identification of individuals that could 
benefit from future therapies based on NCoR/IKK function 
modulation. Moreover, differences in the expression 
profiles associated with the presence or absence of 
nuclear NCoR in MM might not only give insight in the 
pathogenic pathways underlying MM development or 
progression, but also provide a mechanism-driven base 
for specific therapeutic intervention of selected patients.
METHODS
Patients
A total of 63 patients with primary invasive MM, 
specifically, 38 males and 25 females, with a median age 
of 69 years (ranging from 31 to 98) were included in the 
study. Clinical and pathological data have been gathered 
from a single institution (Parc de Salut MAR from 
Barcelona, Spain). Cases analyzed in this study include 
all patients with invasive MM that were recruited during 
the period 2000–2009 from Parc de Salut Mar-Biobank, 
only excluding non-conventional histological variants or 
doubtful cases of melanocytic proliferations with unknown 
significance. Cases were not selected on the basis to any 
specific clinical or histopathological criteria.
Forty-six patients presented a Breslow index > 
1 mm (mean: 2.24 mm; median 1.4 mm). Fourteen 
tumors were ulcerated and 31 showed a mitotic index > 
1 mitoses/mm2, 18 cases presented with 1 mitosis/mm2 
and no mitoses were seen in the remaining 14 cases. 
Patients were periodically controlled for a median 
follow-up of 59.4 months. Forty-nine patients were 
classified in stage I–II and 14 were in stages III–IV at 
diagnosis, and from those in which sentinel lymph node 
biopsies were performed (32 out of 63 patients), 19% 
(6 patients) presented micrometastases. During the 
follow-up period, 48 patients did not progress in the 
disease from the initial stage (IA–IIIA), whereas 15 cases 
(24%) progressed to more advanced stages. These clinical 
data are representative of an average MM population.
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Immunohistochemistry (IHC) and 
immunofluorescence (IF)
IHC and IF analysis of the MM samples and cell 
lines was performed using the following antibodies: 
Goat polyclonal anti-NCoR (sc-C20) and p65-NF-κB 
(sc-372) from Santa Cruz biotechnology inc. Antigen 
retrieval was achieved by boiling the samples for 10 
minutes in Tris/EDTA buffer at pH 9.0. Tissue sections 
were incubated overnight with the corresponding primary 
antibody (in PBS plus 0.1% BSA), and then extensively 
washed and incubated with the secondary biotin-labeled 
antibodies (1:200) at room temperature for 30 minutes. 
Immunoreactivity was revealed using a streptavidin-
biotin-peroxidase complex (sABC-HRP, DakoCytomation 
K0377; 1:100; DAKO) or Alcaline phosphatase, and 
developed with diaminobenzidine (DAB) solution 
(Sigma–Aldrich, Zwijndrecht, The Netherlands) or Fast 
Red TR (Sigma), respectively. All sections were then 
counterstained with hematoxylin, and Melan-A was used 
to confirm the neoplastic (melanocytic) nature of the cells 
stained for NCoR and p65-NF-κB. Cells were counted 
directly under a 40× magnification and the percentage of 
tumor cells that exhibited positive immunoreactivity was 
determined. At least 100 neoplastic cells were counted 
for each sample. The mean percentage obtained from 3 
independent reads by 2 pathologists was recorded. Nuclear 
and cytoplasmic staining was evaluated separately. Cell 
staining scores were analyzed as percentages of cells in 
each degree of staining. For nuclear NCoR determination 
only the number (percentage) of nuclei with moderate 
to intense expression was considered. Intense nuclear 
staining was considered when it was comparable to the 
non-tumor samples used as controls. Moderate refers to 
positivity that was less intense than normal controls. No 
or light expression was considered when we did not detect 
a consistent staining at the 40× magnification. Staining 
scores were compared using Student’s t-test or analysis of 
variance (ANOVA) and non-parametric U-Mann–Whitney 
was employed when data did not meet the conditions 
of application of these tests. Likewise comparisons in 
which subgroups did not reach the minimum sample size 
Bonferroni corrections were used. Kaplan Meier survival 
curves were calculated using the SPSS program. The 
morphological variables and IHC data were recorded 
and included the histopathological subtype of MM, 
measurements of invasion (Breslow index and Clark 
level), the presence of ulceration, mitotic rate, features of 
regression, intratumor inflammatory infiltrate, the presence 
of microsatellitosis and vascular invasion. In addition, 
40 benign melanocytic lesions (intradermal, junctional 
and dysplastic melanocytic nevi) were used as controls. 
Sample size for comparing two means with unilateral 
contrast, being the percentage of positively stained 
melanocytes the main variable, was calculated according 
the algorithm, n = ((za + z2b)^2 *2*s ^2)/Dm^. We used 
the semi-quantitative Histoscore index: (0x%) + (1x%) + 
(2x%) + (3x%) to perform parametric statistical tests to 
determine the association between nuclear NCoR and p65 
stainings.
WB and IKK inhibitors
Western blot experiments were performed using 
standard methods. The α-NCoR antibody was from 
Abcam (ab58396), α-P-IKKα-Ser180/IKKβ-Ser181 (sc-
23470) and α-Lamin B (sc-6216) were from Santa Cruz 
Biotechnology, and α-tubulin from Sigma. BAY11-7082 
was purchased from Calbiochem (7082) and used at the 
indicated concentrations.
Obtaining and processing somatic mutations 
datasets
We obtained 51 somatic mutations datasets from the 
International Cancer Genome Consortium (ICGC), the 
Cancer Genome Atlas (TCGA), and literature searches, 
analogously as described [16]. Nine ICGC datasets were 
downloaded directly from the Data Coordination Centre 
(DCC) Biomart [19]. Nineteen TCGA datasets were 
downloaded from the Synapse platform (syn1729383) 
as MAF files. We obtained thirteen additional datasets 
from a comprehensive recent study of tumor mutational 
signatures [20]. Finally, a manual PubMed search allowed 
us to identify ten other somatic mutations datasets that 
had been produced by research groups outside these 
large initiatives. Among these 51 datasets, there were two 
MM studies, one carried out by the Broad Institute (and 
obtained via [20]) and a second one developed within the 
TCGA (downloaded from Synapse) totaling 369 samples.
Running the IntOGen-mutations pipeline
The ICGC and mutational signatures datasets were 
obtained already in the tab-separated format accepted by 
the pipeline. The MAF files obtained from synapse were 
parsed and transformed to this tab-separated format. 
We manually parsed supplementary files of the papers 
reporting individual studies to extract the lists of somatic 
mutations detected across tumor samples and then 
transformed them into tab-separated files. The first part of 
the IntOGen-mutations pipeline [16] assesses the potential 
functional impact of somatic mutations detected across 
the cohort of tumor samples. The Ensembl Variant Effect 
Predictor (VEP, v.70 script [21] and pre-computed cache 
files, downloaded from the Ensembl ftp site (ftp://ftp.
ensembl.org/pub/), are used to determine the consequences 
of somatic mutations to annotated protein-coding genes. 
We employed the results of this first part to compute the 
number of samples with mutations in NCoR in different 
datasets –subsequently aggregated per tumor type–, as 
well as their consequence types. The pipeline also obtains 
Oncotarget9293www.impactjournals.com/oncotarget
SIFT [22] and PolyPhen2 [23] functional impact scores 
from the VEP. Pre-computed Mutation Assessor [24] 
functional impact obtained from its author’s webserver 
(www.mutationassessor.org) during the installation of the 
pipeline are queried locally during execution. The pipeline 
implements an expression filter to disregard genes that are 
not expressed across the tumor types analyzed.
The Oncodrive FM approach has also been 
described elsewhere [17]. Briefly, Oncodrive FM receives 
as input the list of synonymous, stop-gained, stop-lost, 
non-synonymous and frameshift-indel mutations and their 
corresponding SIFT, PolyPhen2 and Mutation Assessor 
scores. Then, it assesses whether any gene shows a trend 
toward the accumulation of mutations with high functional 
impact as compared to the background distribution of 
these functional impact scores in all mutations detected 
across the cohort of tumor samples (FM bias). For each 
functional impact score method included in the pipeline, 
the method produces an empirical p-value that evaluates 
this FM bias. These three p-values are subsequently 
combined using Fisher’s approach to produce one 
integrated p-value for each gene. To account for possible 
non-dependence between the three p-values included in 
the combination, the IntOGen-mutations web discovery 
tool considers as significant those with a false discovery 
rate (FDR) below 0.01. We checked specifically whether 
NCoR exhibits the FM bias in any mutational dataset. 
(When more than one dataset of the same tumor type was 
available, we retained only the most significant q-value: 
see Supplementary Table S2)
Gene ontology analysis of differentially 
expressed genes
Overrepresentation analysis of Gene Ontology 
(GO) categories and pathways was used to explore the 
functions associated with NCoR regulated genes in MM. 
Gene set enrichment analysis (GSEA) identifies gene sets 
consisting of co-regulated genes; Gene Ontology (GO) 
gene sets are based on ontologies and do not necessarily 
comprise co-regulated genes. Gene sets collected from 
various sources such as online pathway databases, 
publications in PubMed, and knowledge of domain 
experts. The gene set page for each gene set lists its 
source. Computational gene sets defined by mining large 
collections of cancer-oriented microarray data. Gene sets 
are named by GO term and contain genes annotated by 
that term. (http://www.broadinstitute.org/gsea/msigdb/
collections.jsp#C2); IPA: (http://www.ingenuity.com).
Ethical considerations
The approval for the study was provided by 
the Comitè Ètic d’ Investigació Clínica from Institut 
Municipal d’Assistència Sanitària (CEIC-PSMAR) and 
written informed consent was obtained from all patients 
according to the National and International guidelines 
(code of ethics, Declaration of Helsinki) and the legal 
regulations on data privacy (Law 15/1999 of 13 December 
on the Protection of Personal Data) were considered. All 
samples stored in the tumor bank (Hospital del Mar in 
Barcelona, Spain).
Statistical analysis
Non-parametric Kruskal–Wallis test and Mann–
Whitney U test were used to determine the association 
between NCoR and various categorical clinicopathologic 
parameters. To assess the relationship between NCoR with 
Breslow index and mitotic rate, Spearman’s correlation 
coefficient was performed. Kaplan–Meier method with 
a Log-Rank test was used to compare overall survival, 
disease specific survival and disease free survival among 
groups. P values less than 0.05 were considered as 
statistically significant. Analysis performed with SPSS 
18.0 (IBM Corp.).
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